Sudeep Pharma Limited has released its comprehensive Q3FY26 investor presentation and announced an upcoming earnings call scheduled for February 9, 2026, at 11:00 a.m. to discuss operational and financial performance for the third quarter and nine months ended December 31, 2025. The company submitted the presentation to stock exchanges under Regulation 30 of SEBI LODR Regulations and made it available on its official website.

Financial Performance Highlights

The company's consolidated financial results reveal impressive growth across key metrics for the quarter ended December 31, 2025. The performance demonstrates the company's strengthening market position and operational efficiency.

Nine-Month Performance Overview

For the nine months ended December 31, 2025, the consolidated results show sustained growth momentum with total income reaching ₹482.10 crores compared to ₹350.00 crores in the previous year, representing 38% growth. Net profit after tax for the nine-month period stood at ₹125.70 crores versus ₹94.50 crores, marking 33% growth. The earnings per share for the nine-month period was ₹11.32 compared to ₹8.71 in the corresponding period.

Strategic Battery Materials Expansion

The company successfully conducted a groundbreaking ceremony for its Battery Materials Plant at Dahej, Gujarat on January 23, 2026. The project details include:

Capacity Expansion and Growth Strategy

The presentation outlined the company's ambitious capacity expansion plans across multiple segments. The total manufacturing capacity is expected to grow from 65,000 MT in FY25 to 1,23,700 MT in FY26, primarily driven by the greenfield project addition of 51,200 MT in pharma, food & nutrition segment and NSS capacity addition of 7,500 MT in specialty ingredients.

Regulatory Compliance and Governance

Company Secretary and Compliance Officer Dimple Mehta confirmed the submission of the Q3FY26 result presentation to both NSE (Scrip Symbol: SUDEEPPHRM) and BSE (Scrip Code: 544619) on February 7, 2026. The earnings call is scheduled to provide detailed insights into the company's operational and financial performance, with the presentation accessible through the company's website at https://www.sudeeppharma.com/ .

Source:

Sudeep Pharma Limited has officially rescheduled its earnings call with analysts and investors to discuss the company's Q3FY26 operational and financial performance. The pharmaceutical company made this announcement through a regulatory filing under Regulation 30 of the SEBI Listing Regulations, 2015.

Rescheduled Earnings Call Details

The company has provided updated scheduling information for its earnings call, which was initially announced on February 2, 2026. The rescheduled call will focus on the operational and financial performance for the quarter and nine months ended December 31, 2025.

Management Participation

The conference call will feature key members of Sudeep Pharma's senior management team who will engage with analysts and investors to provide insights into the company's performance and business outlook.

Key Management Participants:

• Mr. Sujit Bhayani - Managing Director
• Mr. Shanil Bhayani - Director
• Mr. Ketan Vyas - Chief Financial Officer

Access Information

IIFL Capital is organizing the conference call and has provided multiple access options for participants across different regions. The company has made arrangements for both domestic and international participants with dedicated phone lines and online access.

Regulatory Compliance

The announcement was made in compliance with regulatory requirements, with Company Secretary and Compliance Officer Dimple Mehta signing the official communication. The earnings call invite has been hosted on the company's website at www.sudeeppharma.com for easy access by stakeholders.

For additional information regarding the conference call, participants can contact Ranjit Cirumalla at IIFL Capital via email at ranjit.cirumalla@iiflcap.com or by phone at +91 22 4646 4654.